Alzheimer's drug TRx0237 put to the test in large trial
Disease control
Completed
This study tested a drug called TRx0237 in 598 people with Alzheimer's disease. Participants received either a low or high dose of the drug or a placebo for 12 months, followed by another 12 months where everyone could get the drug. The goal was to see if the drug could slow down…
Phase: PHASE3 • Sponsor: TauRx Therapeutics Ltd • Aim: Disease control
Last updated May 22, 2026 13:53 UTC